Abstracts tagged "Measurement Instrument"

Abstract Number: 0207 • ACR Convergence 2022
Novel Digital Technologies for the Assessment of Objective Measures and PROs in Patients with Rheumatoid Arthritis: A Pilot Study Using Smart Devices and a Bespoke Mobile App
Valentin Hamy¹, Christopher Llop², Christopher W Yee², Luis Garcia-Gancedo³, Aoife Maxwell⁴, Wen-Hung Chen⁵, Ryan Tomlinson³, Priyanka Bobbili², Julien Bendelac², Jessica Landry², Maral DerSarkissian⁶, Mihran Yenikomshian², Elinor A Mody⁷, Mei Sheng Duh² and Rachel Williams³, ¹GlaxoSmithKline, London, United Kingdom, ²Analysis Group Inc, Boston, MA, ³GlaxoSmithKline, Philadephia, ⁴GlaxoSmithKline, Stevenage, United Kingdom, ⁵GlaxoSmithKline, Value Evidence and Outcomes, Philadephia, ⁶Analysis Group Inc, Los Angeles, CA, ⁷Reliant Medical Group, Worcester, MA
Background/Purpose: RA symptoms are typically only assessed intermittently in clinical practice and clinical trials. Digital technologies (wearables, smartphones) can facilitate continuous remote monitoring of patients'…
Abstract Number: 0269 • ACR Convergence 2022
Practical Cut-off Points for Using the Rheumatoid Arthritis Impact of Disease (RAID) Questionnaire in Remote Consult Triage
Marijke van den Dikkenberg¹, Martijn Kuijper², Marc Kok¹, Deirisa Lopes Barreto² and Angelique Weel¹, ¹Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, ²Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam
Background/Purpose: In modern Rheumatoid Arthritis (RA) care remote consults (via phone or video call) are increasing. Whereas the Disease Activity Scores (DAS) requires a patient…
Abstract Number: 0571 • ACR Convergence 2022
National Rollout of a Medication Safety Dashboard to Improve Testing for Latent Infections Among Biologic/targeted Synthetic DMARD Users Within the Veterans Health Administration: Initial Results
Anna Montgomery¹, Gary Tarasovsky², Mary Whooley², Jennifer Barton³, Karla Miller⁴, Holly Mitchell⁵, Jo Dana², Kimberly Reiter⁶, Elizabeth Wahl⁷, Karine Rozenberg-Ben-Dror⁸, Jing Li⁹ and Gabriela Schmajuk¹⁰, ¹University of California San Francisco, Reno, NV, ²San Francisco VA Medical Center, San Francisco, CA, ³VA Portland Health Care System/OHSU, Portland, OR, ⁴University of Utah Division of Rheumatology/VA Salt Lake City Health Care, Salt Lake City, UT, ⁵Ralph H. Johnson VA Hospital, Mount Pleasant, SC, ⁶Albuquerque VA Medical Center, Albuquerque, NM, ⁷VA Puget Sound Healthcare System, Seattle, WA, ⁸Greater Lakes Region/VISN 12 Dept Veterans Affairs, Hines, IL, ⁹University of California, San Francisco, San Francisco, CA, ¹⁰UCSF / SFVA, San Francisco, CA
Background/Purpose: Guidelines recommend testing for latent hepatitis B virus (HBV), hepatitis C virus (HCV), and tuberculosis (TB) infection prior to initiating biologics or targeted synthetic…
Abstract Number: 0803 • ACR Convergence 2022
Performance of Adenosine Deaminase Activity in Sinovial Fluid for the Early Diagnosis of Tuberculous Arthritis: A Meta Analysis
Juan Carlos Cortés-Quiroz¹, Javier Ena², José Antonio Bernal³ and José Rosas⁴, ¹Marina Baixa Hospital, Mutxamel, Spain, ²Department of Internal Medicine. Marina Baixa Hospital, Villajoyosa, Spain, ³Rheumatology Department. Marina Baixa Hospital, Alicante, Spain, ⁴Rheumatology Department, Hospital Marina Baixa, Villajoyosa, Spain
Background/Purpose: Adenosine deaminase (ADA) activity has shown good performance in diagnosing pleural, peritoneal, and meningeal tuberculosis. This study aimed to evaluate the performance of measuring…
Abstract Number: 1013 • ACR Convergence 2022
Discriminatory Capacity of the ASAS Health Index in Patients with Axial Spondyloarthritis Treated in a Tight Control Setting versus Standard of Care
Uta Kiltz¹, Anna Molto², Clementina Lopez-Medina³, Maxime Dougados⁴, Désirée van der Heijde⁵, Annelies Boonen⁶, Filip Van den bosch⁷ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology Department, Cochin Hospital, APHP, Paris, France, ³Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ⁴Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁶Maastricht University Medical Centre, Maastricht, Netherlands, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium
Background/Purpose: Improvement in functioning and health as assessed by the ASAS Health Index (HI) is an important outcome of interventions in patients with axial spondyloarthritis…
Abstract Number: 1232 • ACR Convergence 2022
Reliability and Validity of Single Axial Slice vs. Multiple Slice Quantitative Measurement of the Volume of Effusion-Synovitis on 3T Knee MRI in Knees with Osteoarthritis
Greg Gilles¹, Arjun Vohra¹, Chelsea Caruso¹, Dagoberto Robles¹, Mihra Taljanovic¹, Jeffrey Duryea², Erin Ashbeck¹, Edward Bedrick³ and Kent Kwoh⁴, ¹University of Arizona Arthritis Center, Tucson, AZ, ²Brigham and Women's Hospital, Boston, MA, ³Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ⁴University of Arizona, Tucson, AZ
Background/Purpose: Effusion-synovitis (ES) on knee MRI has been identified as an important biomarker of OA. Semi-automated software methods offer objective measurements of ES volume on…
Abstract Number: 1246 • ACR Convergence 2022
Improving Radiologic Interpretation of Diffuse Lung Disease in Pediatric Rheumatologic (PR) Patients Using Trained Scoring with Semi-quantitative Chest Computed Tomography (CT) Analysis
Michal Cidon¹, Beverley Newman², Terry Robinson³, Paul Iskander⁴, Paul Thacker⁵, Evan Zucker², Tzielan Lee⁶ and Rex Moats³, ¹Children's Hospital Los Angeles, Los Angeles, CA, ²Stanford Children's Health, Stanford, CA, ³Children's Hospital of Los Angeles, Los Angeles, CA, ⁴University of California Los Angeles, Los Angeles, CA, ⁵Mayo Clinic, Rochester, MN, ⁶Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: We presented preliminary data in 2021 to support the feasibility of using a semi-quantitative chest CT scoring system (Pediatric Rheumatologic Diffuse Lung Disease Score…
Abstract Number: 1366 • ACR Convergence 2022
Developing a Mobile App to Facilitate Disease Activity Assessment in Localized Scleroderma
Suzanne Li¹, Xiaohu Li², Tara Lozy³ and Jiajun Chen⁴, ¹Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ, ²Stevens Institute of Technology, Hoboken, NJ, ³Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, ⁴One Node Lab, League City, TX
Background/Purpose: Juvenile localized scleroderma (jLS) is an inflammatory and fibrosing disease that causes severe morbidity (e.g., hemiatrophy, arthropathy, seizures), with functional impairment found in >25%…
Abstract Number: 2054 • ACR Convergence 2022
Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process
Kathryn Connelly¹, Laura Eades², Rachel Koelmeyer³, Darshini Ayton³, Vera Golder², Rangi Kandane-Rathnayake², Kate Gregory-Wong³, Hussein Al-Mossawi⁴, Jeanette Andersen⁵, Cynthia Aranow⁶, Laurent Arnaud⁷, Anca Askanase⁸, Subhashis Banerjee⁹, Catherine Barbey¹⁰, Hermine Brunner¹¹, Joy Buie¹², Laurie Burke¹³, Alain Cornet¹⁴, Karen Costenbader¹⁵, Maria Dall'Era¹⁶, Khadija Dantata¹⁷, Nikolay Delev⁹, Ann Eldred¹⁸, Alan Friedman¹⁹, Richard Furie²⁰, Sandra Garces²¹, Dennis Grasela²², Heath Guay²³, Oliver Guenther²⁴, Maria Juarez²⁵, Shelly Kafka²⁶, Kenneth Kalunian²⁷, Elaine Karis²⁸, Youmna Lahoud²⁹, Catharina Lindholm³⁰, Jeffrey Lockman³¹, Charlotte Lupton³², Justine Maller³³, Ashley Marion³⁴, Patrick Marquis³⁵, Joan Merrill³⁶, Thomas Morel³⁷, Marta Mosca³⁸, Yulia Pincus³⁹, Samantha Pomponi⁴⁰, Guillermo Pons-Estel⁴¹, Jorge Ross Terres³³, Cailin Sibley⁴², Maria Silk⁴³, Sanjeev Roy⁴⁴, Lee S Simon⁴⁵, Alessandro Sorrentino⁴⁶, Christian Stach⁴⁷, George Stojan⁴⁸, Ying Sun²⁴, Yoshiya Tanaka⁴⁹, Erik Thomas⁵⁰, Ronald van Vollenhoven⁵¹, Cristina Vazquez Mateo⁵⁰, Edward M Vital⁵², Victoria Werth⁵³, Eric Zollars²⁸, Qing Zuraw⁵⁴ and Eric Morand⁵⁵, ¹Monash Health, Camberwell, Australia, ²Monash University, Clayton, Australia, ³Monash University, Melbourne, Australia, ⁴AstraZeneca, Bucks, United Kingdom, ⁵Lupus Europe, Lupus DK, EULAR PARE, ERN ReCONNECT, Brussels, Belgium, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Hautepierre Hospital, University Hospital of Strasbourg, Rheumatology, Strasbourg, France, ⁸Columbia University Medical Center, New York, NY, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Biogen, Baar, Switzerland, ¹¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ¹²Lupus Foundation of America, Charleston, SC, ¹³LORA Group, Royal Oak, MD, ¹⁴Lupus Europe, Brussels, Belgium, ¹⁵Brigham and Women's Hospital, Boston, MA, ¹⁶University of California, Division of Rheumatology, San Francisco, CA, ¹⁷Lupus Foundation of America, Richmond Hill, GA, ¹⁸AbbVie, Inc., Lake Bluff, IL, ¹⁹AbbVie, Inc., Libertyville, IL, ²⁰Northwell Health, Great Neck, NY, ²¹Amgen, Inc., Almada, Portugal, ²²Bristol Myers Squibb, Lawrencevile, NJ, ²³AbbVie, Inc., Worcester, MA, ²⁴Merck KGaA, Darmstadt, Germany, ²⁵UCB Pharma, Slough, United Kingdom, ²⁶AbbVie, Inc., Norristown, PA, ²⁷University of California San Diego, La Jolla, CA, ²⁸Amgen, Inc., Thousand Oaks, CA, ²⁹Biogen International GmbH, Milton, MA, ³⁰AstraZeneca, Gothenburg, Sweden, ³¹Bristol-Myers Squibb, New York, NY, ³²AstraZeneca, Cambridge, United Kingdom, ³³Genentech, San Francisco, CA, ³⁴Lupus Foundation of America, Washington, DC, ³⁵Modus Outcomes, Cambridge, MA, ³⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ³⁷UCB Pharma, Brussels, Belgium, ³⁸University of Pisa, Pisa, Italy, ³⁹Janssen, Flemington, NJ, ⁴⁰Bristol Myers Squibb, Lawrence Township, NJ, ⁴¹Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, ⁴²Janssen Research & Development, San Diego, CA, ⁴³Eli Lilly, Carmel, IN, ⁴⁴Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany,⁴⁵SDG LLC, West Newton, MA,⁴⁶AstraZeneca, Sollentuna, Sweden, ⁴⁷UCB Pharma, Monheim, ⁴⁸UCB Pharma, Baltimore, MD, ⁴⁹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁵⁰EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, ⁵¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵³University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁵⁴Janssen Research and Development, LLC, Spring House, PA, ⁵⁵Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia
Background/Purpose: Most late-phase randomised controlled trials (RCTs) of novel drugs for systemic lupus erythematosus (SLE) have failed to meet their primary endpoint or shown contradictory…
Abstract Number: 2058 • ACR Convergence 2022
Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
Stefan Perera¹, Jiandong Su², Kathleen Bingham³, Mahta Kakvan¹, Maria Carmela Tartaglia⁴, Leslet Ruttan⁵, Joan Wither¹, May Choi⁶, Simone Appenzeller⁷, Dorcas Beaton⁸, Dennisse Bonilla², Patricia Katz⁹, Robin Green⁵, Michelle Barraclough¹⁰ and Zahi Touma², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁷Unicamp, Campinas, São Paulo, Brazil, ⁸Institute for Work & Health, Toronto, ON, Canada, ⁹UCSF, San Rafael, CA, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is prevalent in SLE and negatively impacts social and occupational engagement. There is a need for a patient-reported outcome measure (PROM)…
Abstract Number: 2142 • ACR Convergence 2022
Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial
William Tillett¹, Laura Coates², Mohamed Sharaf³, Marlies Neuhold⁴, Elke Theander⁵, Paul Bergmans⁶, May Shawi⁷, Michelle Perate⁸, Christine Contré⁹ and Philip Helliwell¹⁰, ¹Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ⁴Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁵Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, ⁶Formerly at Janssen, Breda, Netherlands, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Janssen Scientific Affairs, LLC, Horsham, PA, ⁹Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ¹⁰Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Accurate assessment of psoriatic arthritis (PsA) disease activity in clinical practice requires a feasible, continuous, multidimensional composite instrument to assess key domains of this…
Abstract Number: 1731 • ACR Convergence 2021
Construction and Validation of a Reproductive Health Questionnaire for Women with Rheumatic Diseases
Abraham Yair Lujano-Negrete¹, Luz Ferandanda Gutierrez-Leal², Luis Gerardo Espinosa-Banuelos³, Cassandra Michele Skinner-Taylor¹, Lorena Perez-Barbosa⁴, Ingris Peláez-Ballestas⁵, Eugenio Salvador Barriga-Maldonado⁶, Martha Cecilia Rodriguez-Ruiz¹, Sofía Jezzini-Martínez¹, Selene Maribel Delgado-Ayala¹, Jesus Cardenas-de La Garza⁴ and Dionicio Galarza-Delgado⁴, ¹Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Faculty of Medicine and University Hospital Dr. Jose Eleuterio Gonzalez, UANL, Monterrey, Mexico, ⁴Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, ⁵Hospital General de Mexico "Dr. Eduardo Liceaga", Mexico, Mexico, ⁶Hopsital Universitario Dr. José Eleuterio González, Monterrey, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARDs) commonly affect women of childbearing age. Active maternal disease in the months prior to conception increases the risk of flares…
Abstract Number: 1893 • ACR Convergence 2021
“From Where I Stand”: Using Multiple Anchors Yields Different Benchmarks for Meaningful Improvement and Worsening in the Rheumatoid Arthritis Flare Questionnaire (RA-FQ)
Susan Bartlett¹, Vivian Bykerk², Orit Schieir³, Marie-France Valois¹, Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward Keystone⁸, Janet Pope⁹, Diane Tin¹⁰, Carter Thorne¹¹, Clifton Bingham¹² and CATCH Investigators¹³, ¹McGill University, Montréal, QC, Canada, ²Hospital for Special Surgery, New York, NY, ³Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁹University of Western Ontario, London, ON, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD, ¹³Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada
Background/Purpose: The RA-FQ is a patient-reported measure of current disease activity in RA that can be used to identify disease flares. The RA-FQ queries pain,…
Abstract Number: 0176 • ACR Convergence 2021
Semi-quantitative Chest Computed Tomography (CT) Analysis in Pediatric Rheumatologic (PR) Patients with Diffuse Lung Disease
Michal Cidon¹, Terry Robinson², Beverley Newman³, Paul Iskander², Paul Thacker⁴, Evan Zucker³, Brian Bartholmai⁴, Dnyanesh Tipre², Tzielan Lee⁵, Rajdeep Pooni⁶ and Rex Moats², ¹Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital of Los Angeles, Los Angeles, CA, ³Stanford Children's Health, Stanford, ⁴Mayo Clinic, Rochester, MN, ⁵Stanford University School of Medicine, Palo Alto, CA, ⁶Stanford Children's Health, Palo Alto, CA
Background/Purpose: Spiral chest CT (SCT) is commonly used to evaluate subclinical lung disease in pediatric rheumatology. However, there are no validated scoring tools to objectively…
Abstract Number: 0251 • ACR Convergence 2021
A Comparative Study of the Validity of the DAS28-ESR and JADAS-27 Disease Activity Assessment Indexes for Juvenile Idiopathic Arthritis in Transition and Adults
Takako Miyamae¹, Eiichi Tanaka¹, Eisuke Inoue², Katsunori Ikari¹ and Masayoshi Harigai³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Showa University, Tokyo, Japan, ³Tokyo Women's Medical University School of Medicine, Tokyo, Japan
Background/Purpose: The 2020 Rheumatoid Arthritis Clinical Practice Guidelines by the Ministry of Health, Labour, and Welfare Research Group recommends the JADAS27 as a measure of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].